Genentech-A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF THE RANIBIZUMAB PORT DELIVERY SYSTEM IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WHO HAVE COMPLETED A GENENTECH SPONSORED STUDY